In a new, in-depth commentary recently published in Pharmaceutical Market Europe, PHE Senior Director Jason Shafrin argues for real-world evidence (RWE) to become the gold standard of scientific evidence and health technology assessments.

“RWE provides an opportunity to accelerate drug approval, monitor treatment safety, and appropriately price medications,” Shafrin writes.

To read the complete commentary, please click here.